Acrolein consumption induces systemic dyslipidemia and lipoprotein modification

Journal Article · Mon Feb 15 04:00:00 EST 2010 · Toxicology and Applied Pharmacology

DOI:https://doi.org/10.1016/j.taap.2009.12.010· OSTI ID:21344859

Barski, Oleg A; Lesgards, Jean-Francois ^[1]; Juvan, Peter; Rezen, Tadeja; Rozman, Damjana ^[2]; Prough, Russell A ^[3]; Vladykovskaya, Elena; Liu, SiQi; Srivastava, Sanjay ^[1]; Bhatnagar, Aruni ^[1]

---

1. Diabetes and Obesity Center, University of Louisville, Louisville, KY 40202 (United States)
2. Centre for Functional Genomics and Bio-Chips (CFGBC), Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Zaloska 4, SI-1000 Ljubljana (Slovenia)
3. Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY 40202 (United States)

Aldehydes such as acrolein are ubiquitous pollutants present in automobile exhaust, cigarette, wood, and coal smoke. Such aldehydes are also constituents of several food substances and are present in drinking water, irrigation canals, and effluents from manufacturing plants. Oral intake represents the most significant source of exposure to acrolein and related aldehydes. To study the effects of short-term oral exposure to acrolein on lipoprotein levels and metabolism, adult mice were gavage-fed 0.1 to 5 mg acrolein/kg bwt and changes in plasma lipoproteins were assessed. Changes in hepatic gene expression related to lipid metabolism and cytokines were examined by qRT-PCR analysis. Acrolein feeding did not affect body weight, blood urea nitrogen, plasma creatinine, electrolytes, cytokines or liver enzymes, but increased plasma cholesterol and triglycerides. Similar results were obtained with apoE-null mice. Plasma lipoproteins from acrolein-fed mice showed altered electrophoretic mobility on agarose gels. Chromatographic analysis revealed elevated VLDL cholesterol, phospholipids, and triglycerides levels with little change in LDL or HDL. NMR analysis indicated shifts from small to large VLDL and from large to medium-small LDL with no change in the size of HDL particles. Increased plasma VLDL was associated with a significant decrease in post-heparin plasma hepatic lipase activity and a decrease in hepatic expression of hepatic lipase. These observations suggest that oral exposure to acrolein could induce or exacerbate systemic dyslipidemia and thereby contribute to cardiovascular disease risk.

• OSTI ID: 21344859
• Journal Information: Toxicology and Applied Pharmacology, Journal Name: Toxicology and Applied Pharmacology Journal Issue: 1 Vol. 243; ISSN TXAPA9; ISSN 0041-008X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
ACROLEIN
ALDEHYDES
AMIDES
AMINES
ANIMALS
ANTICOAGULANTS
AZOLES
BIOLOGICAL MATERIALS
BLOOD
BODY
BODY FLUIDS
CARBOHYDRATES
CARBONIC ACID DERIVATIVES
CARBOXYLESTERASES
CARDIOVASCULAR DISEASES
CHOLESTEROL
CHROMATOGRAPHY
CREATININE
DIGESTIVE SYSTEM
DISEASES
DRINKING WATER
DRUGS
ENZYMES
ESTERASES
ESTERS
GLANDS
GROWTH FACTORS
HEMATOLOGIC AGENTS
HEPARIN
HETEROCYCLIC COMPOUNDS
HYDROGEN COMPOUNDS
HYDROLASES
HYDROXY COMPOUNDS
IMIDAZOLES
IMINES
LIPASES
LIPIDS
LIPOPROTEINS
LIVER
LYMPHOKINES
MAGNETIC RESONANCE
MAMMALS
MATERIALS
METABOLISM
MICE
MITOGENS
MUCOPOLYSACCHARIDES
NUCLEAR MAGNETIC RESONANCE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANIC PHOSPHORUS COMPOUNDS
ORGANIC SULFUR COMPOUNDS
ORGANS
OXYGEN COMPOUNDS
PHOSPHOLIPIDS
POLYSACCHARIDES
PROTEINS
RESONANCE
RODENTS
SACCHARIDES
SEPARATION PROCESSES
STEROIDS
STEROLS
TRIGLYCERIDES
UREA
VERTEBRATES
WATER